Compare Cytokinetics Inc (CYTK) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Delta Air Lines, Inc. — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Delta Air Lines, Inc. trades at $82.6 (market cap $54.56B). The key difference: Delta Air Lines, Inc. is far larger — about 6.4× Cytokinetics Inc's market cap, and Delta Air Lines, Inc. pays a 1.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Delta Air Lines, Inc. for 97 Days on average.
| CYTK | DAL | |
|---|---|---|
Market Cap | $8.50B | $54.56B |
Volume | 2,395,556 | 6,532,736 |
Sector | Health | Industrials |
52-Week High | $87.26 | $93.66 |
52-Week Low | $54.76 | $55.65 |
Typical Hold Time | 19 Days | 97 Days |
Enterprise Value | $8.60B | $69.88B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Delta Air Lines (DAL) trades at $82.14, down 1.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. DAL maintains solid profitability with 5.78% net margin and 20.12% ROE, while trading at attractive valuations with P/E of 13.76 and P/S of 0.8. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's internet service over Starlink.
DAL presents a compelling value opportunity with strong analyst support (82% buy ratings) and 26% upside to consensus target of $103.36. However, near-term risks include fuel cost volatility, competitive threats to premium customers, and execution challenges. The improving cash flow trend with $1.08B net cash generation in 2025 supports dividend sustainability and operational flexibility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
